Asset
ACORAMIDIS
BRIDGEBIO PHARMA INC. COMMON STOCK
Revenue
No revenue reported in loaded filings.
Clinical trials (11)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04769479 | phase1 | completed | 2021-03-28 | 2021-08-04 | Eidos Therapeutics, a BridgeBio company | A Single Dose Study to Evaluate the Pharmacokinetics of Acoramidis Modified Release Formulations in Healthy Subjects |
| NCT06563895 | phase3 | recruiting | 2025-05-12 | 2031-10-01 | Eidos Therapeutics, a BridgeBio company | Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant |
| NCT07695701 | phase4 | recruiting | 2026-07-01 | 2030-08-01 | Eidos Therapeutics, a BridgeBio company | Cardiac Magnetic Resonance and Echocardiography Study With Acoramidis |
| NCT03860935 | phase3 | completed | 2019-03-19 | 2023-05-11 | Eidos Therapeutics, a BridgeBio company | Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy |
| NCT04418024 | phase3 | withdrawn | 2020-10-21 | 2024-03-31 | Eidos Therapeutics, a BridgeBio company | Efficacy and Safety of AG10 in Subjects with Transthyretin Amyloid Polyneurophathy |
FDA applications (0)
This company has no applications containing this asset.